Genipin derivative as well as preparation method and application thereof
By replacing enol or alkynol with genipin, the problem of genipin's difficulty in crossing the blood-brain barrier is solved, and its anti-inflammatory activity in ischemic stroke is improved. More effective anti-central nerve inflammation treatment options are provided.
Patent Information
- Application Number
- CN202411105127.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-13
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-08-13
AI Technical Summary
Because of its large polarity of the C-1 hydroxyl group, it has low fat solubility and is difficult to cross the blood-brain barrier, limiting its anti-inflammatory effect in the treatment of ischemic stroke.
Jingniping derivatization is generated by substitution reaction of 3-butene-1-ol, 4-pentene-1-ol, 5-hexene-1-ol or 3-butyne-1-ol with genipin. , improves its fat solubility, makes it easier to be transported by the cell membrane and crosses the blood-brain barrier, and exerts the central effect.
The anti-inflammatory activity of jingniping derivatives in LPS-activated BV-2 cells has been significantly improved, providing better anti-central nerve inflammation drug potential, and solving the application limitations of jingniping in the treatment of ischemic stroke.
Smart Images

Figure CN118994084A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of organic synthesis, and in particular relates to a genipin derivative and a preparation method and application thereof. Background Art
[0002] Stroke, as an acute vascular disease, is mainly caused by external force or other factors that lead to sudden rupture or blockage of brain blood vessels, resulting in the inability of blood to flow into the brain normally, and then causing a series of damages to brain tissue. According to relevant data, ischemic stroke accounts for about 70% to 80% of the total stroke patients. As one of the major diseases that seriously endanger life safety, ischemic stroke (CIS) has a high incidence, recurrence rate, and mortality and disability rates. Cerebral ischemia-reperfusion injury (CIRI) is a local brain injury caused by blood reperfusion after ischemic stroke. It usually occurs during the treatment of ischemic diseases and can cause and aggravate brain tissue damage. Ischemic stroke is a serious and common disease worldwide, causing at least 6.671 million deaths or disabilities each year.
[0003] Currently, the main treatments for ischemic stroke are intravenous thrombolysis and intravascular mechanical thrombectomy, but both have strict time requirements, and only a very small number of patients can receive timely and effective treatment. For most patients who exceed the treatment time window, how to restore blood supply to the brain tissue around the infarct and promote the recovery of neurological function is the focus and difficulty of ischemic stroke treatment, and is also the key to improving the prognosis of ischemic stroke patients.
[0004] Related studies have shown that cerebral ischemia-reperfusion injury (CIRI) is a complex and interrelated cascade reaction process, which covers multiple aspects such as oxidative stress, cell apoptosis and inflammatory response. In traditional Chinese medicine theory, CIRI belongs to the category of "stroke". Depression turns into heat, and heat toxins invade the brain vessels and cause stroke. Therefore, the method of clearing heat and detoxifying is an effective means to treat stroke. Gardeniae Fructus is the dried mature fruit of Gardeniajasminoides Ellis, a plant of the Rubiaceae family. It is yellow or orange-red in color. Gardenia was first recorded in the "Shennong Bencao Jing". According to the ancient book "Shennong Bencao Jing", gardenia has been highly respected for its unique medicinal value since ancient times. Its effects include purging fire and relieving restlessness, clearing heat and promoting diuresis, cooling blood and detoxifying. Numerous studies at home and abroad have confirmed that gardenia has significant antipyretic and anti-inflammatory effects, as well as blood pressure and lipid-lowering effects, and blood sugar-lowering effects, and has a clear protective effect on the liver, blood vessels, nerves, etc. According to research reports, genipin also has similar neuroprotective effects and other anti-central nervous system disease effects as gardenia glycosides. However, due to the large polarity of the hydroxyl group of genipin C-1, it has low lipid solubility, is not easily transported by cell membranes, and is not easy to cross the blood-brain barrier to exert central nervous system drug effects. It cannot exert a good anti-inflammatory effect, which limits the application of genipin. Summary of the invention
[0005] In view of this, the object of the present invention is to provide a genipin derivative and a preparation method and application thereof. The present invention uses 3-butene-1-ol, 4-pentene-1-ol, 5-hexene-1-ol or 3-butyn-1-ol to replace the H atom on the C-1 hydroxyl group of genipin, and the genipin derivative has good anti-inflammatory activity.
[0006] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0007] The present invention provides a genipin derivative, the structural formula of the genipin derivative is shown in Formula I:
[0008]
[0009] In formula I, R is H 2 C=CH-CH 2 -CH 2 -、H 2 C=CH-CH 2 -CH 2 -CH 2 -、H 2 C=CH-CH 2 -CH 2 -CH 2 -CH 2 - or CH≡C-CH 2 -CH 2-.
[0010] The present invention also provides a method for preparing the genipin derivative described in the above technical solution, comprising the following steps:
[0011] The genipin, alcohol, organic solvent and catalyst are mixed to carry out substitution reaction to obtain a genipin derivative;
[0012] The alcohol includes an enol or an alkynol, the enol includes 3-butene-1-ol, 4-pentene-1-ol or 5-hexene-1-ol, and the alkynol includes 3-butyn-1-ol.
[0013] Preferably, when the alcohol is an enol, the catalyst is p-toluenesulfonic acid.
[0014] Preferably, the molar ratio of genipin to p-toluenesulfonic acid is 1:1.1 to 1:5.
[0015] Preferably, when the alcohol is an alkynol, the catalyst is boron trifluoride etherate.
[0016] Preferably, the molar ratio of genipin to boron trifluoride ether is 1:1.1 to 1:5.
[0017] Preferably, the temperature of the substitution reaction is -20 to 0°C and the time is 4 to 5 hours.
[0018] Preferably, the organic solvent includes dichloromethane or dichloroethane, and the dosage ratio of genipin to the organic solvent is 1 mmol: (5-20) mL.
[0019] Preferably, the substitution reaction further includes quenching the reaction, extraction, drying and purification, wherein the purification is silica gel column purification, the eluent of the silica gel column purification is a mixture of petroleum ether and ethyl acetate, and the volume ratio of petroleum ether to ethyl acetate in the mixture is 3:1 to 8:1.
[0020] The present invention also provides the use of the genipin derivatives described in the above technical solution or the genipin derivatives obtained by the preparation method described in the above technical solution in the preparation of drugs for treating central nervous system inflammation.
[0021] Compared with the prior art, the present invention has the following beneficial effects:
[0022] The present invention provides a genipin derivative, the structural formula of the genipin derivative is shown in Formula I:
[0023]
[0024] In formula I, R is H 2 C=CH-CH 2 -CH 2 -、H2 C=CH-CH 2 -CH 2 -CH 2 -、H 2 C=CH-CH 2 -CH 2 -CH 2 -CH 2 - or CH≡C-CH 2 -CH 2 -.
[0025] The present invention uses genipin as a lead compound for structural modification, connects an enol or alkynol unsaturated group, and uses 3-butene-1-ol, 4-pentene-1-ol, 5-hexene-1-ol or 3-butyn-1-ol to replace the H atom on the C-1 hydroxyl group of genipin. The obtained four genipin derivatives containing unsaturated groups have good anti-inflammatory activity and are more suitable for preparing drugs for resisting central nervous system inflammation.
[0026] The present invention explores the effects of these unsaturated group-containing genipin derivatives on the NO content in LPS-activated BV-2 cells, laying a solid theoretical foundation for the subsequent development and synthesis of new anti-neuroinflammatory drugs. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0028] Figure 1 is the hydrogen spectrum of 3-butene-1-ol genipin;
[0029] Figure 2 is the hydrogen spectrum of 4-penten-1-ol genipin;
[0030] Figure 3 is the hydrogen spectrum of 5-hexen-1-ol genipin;
[0031] Figure 4 is the hydrogen spectrum of 3-butyne-1-ol genipin;
[0032] Figure 5 is the NO standard curve;
[0033] Figure 6 is the cell survival rate at different concentrations of genipin;
[0034] Figure 7is the cell survival rate of different concentrations of genipin derivatives, where a is 1-O-(3'-ene-butyl) genipin, b is 1-O-(4'-ene-pentyl) genipin, c is 1-O-(5'-ene-hexyl) genipin, and d is 1-O-(3'-alkynyl-butyl) genipin;
[0035] Figure 8 for the effect of genipin on NO levels;
[0036] Fig. 9 The figure shows the effect of genipin derivatives on the NO level in the LPS-induced BV-2 cell inflammation model, wherein a is 1-O-(3'-ene-butyl) genipin, b is 1-O-(4'-ene-pentyl) genipin, c is 1-O-(5'-ene-hexyl) genipin, and d is 1-O-(3'-alkyne-butyl) genipin. DETAILED DESCRIPTION
[0037] The present invention provides a genipin derivative, the structural formula of the genipin derivative is shown in Formula I:
[0038]
[0039] In formula I, R is H 2 C=CH-CH 2 -CH 2 -、H 2 C=CH-CH 2 -CH 2 -CH 2 -、H 2 C=CH-CH 2 -CH 2 -CH 2 -CH 2 - or CH≡C-CH 2 -CH 2 -.
[0040] The genipin derivatives of the present invention have improved lipid solubility, are more easily transported by cell membranes, easily cross the blood-brain barrier, and exert central nervous system drug effects. The genipin derivatives have good anti-inflammatory activity.
[0041] The present invention also provides a method for preparing the genipin derivative described in the above technical solution, comprising the following steps:
[0042] Genipin, alcohol, organic solvent and catalyst are mixed for substitution reaction to obtain a genipin derivative; the alcohol includes an enol or an alkynol, the enol includes 3-butene-1-ol, 4-pentene-1-ol or 5-hexene-1-ol, and the alkynol includes 3-butyn-1-ol.
[0043] In the present invention, unless otherwise specified, the materials and equipment used are commercially available products in the art.
[0044] In the present invention, when the alcohol is preferably an enol, the catalyst is preferably p-toluenesulfonic acid, and the molar ratio of genipin to p-toluenesulfonic acid is preferably 1:1.1 to 1:5, more preferably 1:2 to 3; the substitution reaction is preferably S N 1 substitution reaction, the S N The temperature of the substitution reaction is preferably -20 to 0°C, and the time is preferably 4 to 5 hours.
[0045] In the present invention, the molar ratio of genipin to enol is preferably 1:1 to 1:3, more preferably 1:2.
[0046] In the present invention, when the alcohol is preferably an alkynol, the catalyst is preferably boron trifluoride ethyl ether, and the molar ratio of genipin to boron trifluoride ethyl ether is preferably 1:1.1 to 1:5, more preferably 1:2 to 3; the substitution reaction is preferably S N 2 substitution reaction, the S N The temperature of the 2-substitution reaction is preferably -20 to 0°C, and the time is preferably 4 to 5 hours.
[0047] In the present invention, it is preferred that genipin, alcohol and organic solvent are first mixed in an ice bath and then the catalyst is added to lower the system temperature and reduce the generation of by-products.
[0048] In the present invention, the molar ratio of genipin to alkynol is preferably 1:1 to 1:3, more preferably 1:2.
[0049] In the present invention, the organic solvent preferably includes dichloromethane or dichloroethane, and the dosage ratio of the genipin to the organic solvent is preferably 1 mmol: (5-20) mL, more preferably 2.21 mmol: 15 mL. The dichloroethane is preferably 1,2-dichloroethane. The organic solvent of the present invention has low toxicity.
[0050] In the present invention, the substitution reaction preferably further includes quenching reaction, extraction, drying and purification.
[0051] In the present invention, the method for quenching the reaction is preferably: mixing the system obtained by the substitution reaction with water. The extraction reagent is preferably dichloromethane, and the number of extractions is preferably 3 times; the drying is preferably drying with a desiccant, and the desiccant is preferably anhydrous sodium sulfate.
[0052] In the present invention, the purification is preferably silica gel column purification, the silica gel particle size of the silica gel column is preferably 200-300 mesh, the eluent of the silica gel column purification is preferably a mixture of petroleum ether and ethyl acetate, and the volume ratio of petroleum ether to ethyl acetate in the mixture is preferably 3:1-8:1, more preferably 5:1.
[0053] The present invention also provides the use of the genipin derivatives described in the above technical solution or the genipin derivatives obtained by the above preparation method in the preparation of drugs for treating central nervous system inflammation.
[0054] Based on the core molecular structure of genipin, the present invention synthesizes a series of genipin derivatives containing unsaturated groups, and conducts preliminary research on their anti-inflammatory activities, providing a reference for finding drugs for preventing and treating brain diseases such as neuroinflammation.
[0055] In order to further illustrate the present invention, the genipin derivatives provided by the present invention and their preparation methods and applications are described in detail below in conjunction with the accompanying drawings and examples, but they should not be construed as limiting the scope of protection of the present invention.
[0056] In the embodiments or application examples of the present invention, the BV-2 cells used are a mouse-derived microglial cell line purchased from Zhejiang Meisen Cell Technology Co., Ltd.
[0057] Example 1 Synthesis of Genipin Derivatives Containing Alkenyl Unsaturated Groups:
[0058] The reaction formula for synthesizing genipin derivatives containing ethylenically unsaturated groups from genipin and enol is shown below:
[0059]
[0060] In a 50 mL round-bottom flask, 0.50 g (2.21 mmol) of 98% genipin by mass, enol (3-butene-1-ol, 4-pentene-1-ol or 5-hexene-1-ol, all 4.42 mmol) and 15 mL of dichloromethane were added in sequence as reaction solvents, and p-toluenesulfonic acid (6.63 mmol) was added dropwise as a catalyst to the genipin-enol reaction system; after reacting for 4 hours, the reaction system was poured into distilled water to quench and terminate the reaction.
[0061] Then, 150 mL of dichloromethane was used for extraction (3 times of extraction, 50 mL each time), the organic phase in the lower layer of the separatory funnel was collected, and washed with saturated sodium chloride solution (3 times) until the solution was transparent, and 5 g of anhydrous sodium sulfate was added for drying. Petroleum ether and ethyl acetate were selected as eluents and mixed in a volume ratio of 5:1; 200-300 mesh silica gel was used, and petroleum ether was used for dissolving and then loading the column to avoid bubbles in the silica gel column; the product was separated from the impurities by silica gel column chromatography to obtain a colorless or light yellow oily liquid, which was the purified genipin derivative containing an olefinic unsaturated group.
[0062] Example 2 Synthesis of genipin derivatives containing alkynyl unsaturated groups:
[0063] The reaction formula for synthesizing genipin derivatives containing alkynyl unsaturated groups from genipin and alkynol is as follows:
[0064]
[0065] In a 50 mL round-bottom flask, 0.50 g (2.21 mmol) of 98% genipin, 3-butyn-1-ol (4.42 mmol) and 15 mL of dichloromethane were added in sequence as a reaction solvent. After reacting in an ice bath for five minutes, boron trifluoride etherate (6.63 mmol) was added dropwise with a syringe. After reacting for 4 hours, the reaction system was poured into distilled water to quench and terminate the reaction.
[0066] Then, 150 mL of dichloromethane was used for extraction (3 times of extraction, 50 mL each time), the organic phase in the lower layer of the separatory funnel was collected, and washed with saturated sodium chloride solution (3 times) until the solution was transparent, and 5 g of anhydrous sodium sulfate was added for drying. Petroleum ether and ethyl acetate were selected as eluents and mixed in a volume ratio of 5:1; 200-300 mesh silica gel was used, and petroleum ether was used for dissolution and column loading to avoid bubbles in the silica gel column; the product was separated from the impurities by silica gel column chromatography to obtain a colorless oily liquid, which was the purified genipin derivative containing an alkynyl unsaturated group.
[0067] Figure 1 is the hydrogen spectrum of 3-butene-1-ol genipin, Figure 2 is the hydrogen spectrum of 4-penten-1-ol genipin, Figure 3 is the hydrogen spectrum of 5-hexen-1-ol genipin, Figure 4 is the hydrogen spectrum of 3-butyne-1-ol genipin; the compounds obtained in Example 1 and Example 2 were analyzed by hydrogen spectrum as follows:
[0068] 1) GP21-O-(3'-ene-butyl) genipin, colorless oily liquid: 1H NMR (CDCl 3 ,600MHz), δ:7.48(s,1H),7.41(s,1H),5.72-5.80(m,2H),5.01-5.11(m,2H),4.51(d,J =8.4Hz,1H),4.22(t,J=7.9Hz,2H),4.13(s,1H),4.01(q,J=7.4Hz,1H),3.69(d,J=4.2H z,1H),3.57(q,J=7.8Hz,1H),3.15(q,J=8.4Hz,1H),2.82-2.87(m,1H),2.57(t,J=2.0H z,1H),2.52(s,1H),2.37(q,J=6.6Hz,1H),2.28(d,J=6.6Hz,1H),2.03(q,J=8.4Hz,1H)
[0069] 2) GP31-O-(4'-ene-pentyl) genipin, yellow oily liquid: 1 H NMR (CDCl 3 ,600MHz), δ:7.44(s,1H),7.37(s,1H),5.70-5.76(m,2H),5.04(d,J=3.0Hz,1H),4.89-4.9 8(m,2H),4.47(d,J=8.4Hz,1H),4.16(t,J=9.0Hz,2H),3.90(q,J=5.4Hz,1H),3.65(d,J=4. 2Hz,1H),3.50(q,J=4.8Hz,1H),3.11(t,J=8.7Hz,1H),2.79-2.83(m,1H),2.53(t,J=8.1Hz ,1H),2.06(q,J=7.2Hz,1H),1.98-2.02(m,2H),1.68(q,J=7.2Hz,2H),1.58(t,J=7.2Hz,1H)
[0070] 3) GP41-O-(5'-ene-hexyl) genipin, yellow oily liquid: 1 H NMR (CDCl 3,600MHz), δ:7.52(s,1H),7.45(s,1H),5.76-5.84(m,1H),4.94-5.10(m,2H),4.54(d,J=8.4Hz,1H),4 .25(d,J=13.8Hz,2H),3.98(d,J=9.6Hz,1H),3.82(d,J=9.0Hz,2H),3.73(d,J=6.0Hz,1H),3.57(d,J=9 .0Hz,1H),3.49(s,1H),3.19(t,J=7.8Hz,1H),3.09(s,1H),2.60(t,J=8.1Hz,1H),2.46(s,1H),2.05- 2.10(m,2H),1.66(t,J=7.8Hz,1H),1.58(t,J=7.5Hz,1H),1.47(q,J=7.8Hz,1H),1.41(t,J=7.8Hz,1H)
[0071] 4) GP51-O-(3'-Alkyne-butyl)genipin, colorless oily liquid: 1 H NMR (CDCl 3 ,600MHz), δ:7.50(s,1H),5.83(s,1H),4.61(d,J=8.4Hz,1H),4.31(q,J=13.0Hz,2H),4.04-4.08(m,1H),3,69-3.73(m, 3H),3.19(q,J=7.8Hz,1H),2.86-2.90(m,1H),2.64(m,1H),2.52-2.55(m,2H),2.43(d,J=2.4Hz,2H),2.04-2.09(m,2H)
[0072] Through organic synthesis, the structure of genipin was modified with genipin as the parent structure: unsaturated groups enol and alkynol were substituted by substitution reaction of enol in p-toluenesulfonic acid and alkynol in boron trifluoride ether to synthesize four genipin derivatives: GP2, GP3, GP4, GP5, with yields of 66.2%, 56.7%, 48.7% and 49.2%, respectively.
[0073] Comparative Example 1
[0074] The catalyst in Example 1 was replaced with boron trifluoride ethyl etherate, and the remaining steps were the same as in Example 1. The reaction formula of boron trifluoride ethyl etherate catalyzing enol and genipin is as follows:
[0075]
[0076] The experimental results show that the yield of the target product is extremely low and it is difficult to obtain a pure product.
[0077] Comparative Example 2
[0078] The 3-butene-1-ol in Example 1 was replaced with 1-butene-3-ol, and the remaining steps were the same as in Example 1. The reaction formula of 1-butene-3-ol and genipin is as follows:
[0079]
[0080] The experimental results show that the reaction between 1-butene-3-ol and genipin is not ideal. There are many by-products but the required amount of main product is very small, and the target product cannot be obtained.
[0081] Application Example 1
[0082] 1. Biological activity evaluation method
[0083] LPS is a type of endotoxin produced by Gram-negative bacteria. One of the most widely used models of inducing neuroinflammation and neurodegeneration is the lipopolysaccharide-induced inflammation model. LPS administration is widely used in the in-depth study of various inflammatory-related diseases and the efficacy testing of inflammatory targeted drugs.
[0084] BV-2 cells are microglia in the mouse nervous system. Microglia are immune-related cells that play a key role in the central nervous system (CNS). Microglia can be deeply involved in the initial stage and subsequent evolution of a variety of CNS-related diseases, especially in secondary injuries caused by inflammation and trauma. They play an indispensable role. Under physiological conditions, microglia maintain a quiescent state to ensure the stability and normal function of their functions. They can monitor and inspect the relevant conditions of the central nervous system. After CIS occurs, microglia located in the brain will be activated and release many kinds of cytotoxic molecules and factors, thereby aggravating brain cell damage. Therefore, the use of LPS-induced BV-2 cells can more simply and clearly observe the effects of genipin derivatives containing unsaturated groups on their effects, and observe whether the synthesized derivatives can improve the inflammatory response of LPS-induced BV-2 cells.
[0085] NO is produced by L-arginine under the action of nitric oxide synthase (NOS) and is widely involved in various physiological and pathological processes of the body. When cerebral ischemia occurs, NO produced by endothelial nitric oxide synthase (eNOS) can relax vascular smooth muscle and help maintain blood flow. BV-2 inflammatory cells induced by LPS will produce NO, which can be used as one of the indicators for preliminary evaluation of anti-inflammatory activity.
[0086] 1. BV-2 cell culture
[0087] (1) Cell recovery
[0088] 1 mL of BV-2 cell sample was taken out of the freezer and then placed securely in a constant temperature water bath set at 37°C for strict thawing. After the thawing process was successfully completed, BV-2 cells were cultured in a special DMEM medium containing 10% FBS (fetal bovine serum) and 1% double antibody (penicillin / streptomycin mixture) to ensure a suitable growth environment for the cells. In order to ensure that the cells can grow normally, the culture dish was placed in a 5% CO 2 In a 37°C constant temperature incubator with gas. During the culture process, the culture medium needs to be replaced every two days to ensure the stability of the cell growth environment. When BV-2 cells grow to confluence in the culture medium and the cell state is confirmed to be good by observation, the next step of cell passaging can be carried out.
[0089] (2) Cell passaging
[0090] To ensure the accuracy of the experiment and cell viability, follow the following steps: First, the culture medium in the culture flask must be completely removed; then, use 2mL of phosphate belanced solution (PBS) to gently rinse the cells twice to remove the residual culture medium components; then, add trypsin to the cells, and to ensure effective digestion of the cells, place them in the trypsin solution for 1 minute. Then, in order to terminate the digestion of trypsin, 3mL of fresh culture medium must be added. Next, transfer the cell suspension to a centrifuge tube and centrifuge at 1200rpm for 3 minutes to allow the cells to precipitate. Finally, transfer the centrifuged cells to new culture medium to complete the entire process. Then culture them under appropriate conditions.
[0091] (3) Cell plating
[0092] In this step of the experimental operation, the BV-2 cells in the growth phase are first centrifuged to effectively separate the supernatant from the precipitate. Subsequently, only the precipitate at the bottom is retained and resuspended in fresh culture medium to ensure cell viability and purity.
[0093] Next, 100 μL of cell suspension was accurately injected into the 96-well cell plate. At the same time, the cell density in each well was strictly controlled to ensure that the number of cells in each well reached 2×10 4 Each group of experiments needs to set up 4 replicate wells to improve the reliability and stability of the experimental results.
[0094] In order to compare the growth and response of cells under different conditions, a control group and a model group (LPS group) were set up. The cells in the control group were cultured under conventional culture conditions, while the cells in the model group were exposed to LPS stimulation to simulate a specific physiological or pathological environment.
[0095] Finally, all wells were placed in CO 2 The cells are cultured in an incubator for 24 hours. During this process, the cells will grow and differentiate in a suitable temperature, humidity and gas environment for subsequent observation and analysis.
[0096] 2. Determination of the inhibition rate of different drug concentrations on BV-2 cells
[0097] BV-2 cells were grown at 2×10 4 The cell density was accurately inoculated into a 96-well plate, which was then properly placed in an incubator for a 24-hour standardized culture. After the initial culture, different concentrations of drugs were added to each well, 3.125, 6.25, 12.5, 25, 50, 100, 200, and 400 μmol / L, and the well plate was placed in the incubator again for a further incubation of 24 hours. Subsequently, 10 μL of CCK-8 reagent was added to each well and incubated for another 2 hours under the same conditions. Finally, the absorbance value of each well was measured at a wavelength of 450 nm using an enzyme reader. To ensure the accuracy and reliability of the results, 4 replicate wells were set up for each group of experiments.
[0098] 3. Determination of NO Levels in BV-2 Cells
[0099] The cells were placed in an incubator and cultured for 24 hours to ensure that the cells were in good growth condition. After that, the cells were taken out and pretreated with drugs at different concentrations of 3.125, 6.25, 12.5, 25, 50, 100, 200, and 400 μmol / L. The duration of pretreatment was 1 hour to ensure that the drugs could fully act on the cells. After the pretreatment, 2 μg / mL of LPS was added to the cells. After the addition of LPS, the cells were incubated for another 24 hours to observe the changes in the cells after stimulation. In order to further understand the metabolic changes of the cells after stimulation, a nitrate reduction test was then performed. A new 96-well cell plate was taken out and 50 μL of cell supernatant was added to it. Then, an equal volume of Griess reagent was added to each well and evenly mixed by shaking. Finally, the absorbance of each well was measured at a wavelength of 550 nm and compared with NaNO 2 The NO standard curve can be used to accurately calculate the NO concentration. Table 1 is the NO standard curve. Figure 5 This is the NO standard curve.
[0100] Table 1 NO standard curve
[0101]
[0102]
[0103] After experimental measurement, the absolute absorbance data corresponding to NO standard solution at different concentrations were obtained, and correlation analysis was performed. The analysis results showed that the correlation coefficient R was as high as 0.9978, indicating that there was an excellent correlation between the measured absolute absorbance and the concentration of NO standard solution.
[0104] 2. Biological Activity Evaluation Results
[0105] 1. Effects of genipin and its derivatives on the proliferation of BV-2 cells
[0106] Figure 6 is the cell survival rate at different concentrations of genipin, Figure 7 Is the cell survival rate of different concentrations of genipin derivatives, where a is 1-O-(3'-ene-butyl) genipin, b is 1-O-(4'-ene-pentyl) genipin, c is 1-O-(5'-ene-hexyl) genipin, and d is 1-O-(3'-alkyn-butyl) genipin; *P<0.05, **P<0.01.
[0107] 2. Effects of genipin derivatives on NO levels in LPS-induced BV-2 inflammation model
[0108] Figure 8 The effect of genipin on NO levels. Fig. 9 The effects of genipin derivatives on the NO level in the LPS-induced BV-2 cell inflammation model, where a is 1-O-(3'-ene-butyl) genipin, b is 1-O-(4'-ene-pentyl) genipin, c is 1-O-(5'-ene-hexyl) genipin, and d is 1-O-(3'-alkyn-butyl) genipin; *P<0.05, **P<0.01.
[0109] The CCK-8 method was used to detect the effects of genipin and its derivatives on the survival rate of BV-2 cells induced by LPS. The data showed that genipin had no effect on the proliferation of BV-2 cells at concentrations of 3.125, 6.25, 12.5, 25, 50, and 100 μmol / L, and had no obvious cytotoxicity. The products 1-O-(3'-ene-butyl) genipin, 1-O-(5'-ene-hexyl) genipin, and 1-O-(3'-alkyne-butyl) genipin had an effect on the proliferation of BV-2 cells at 100 μmol / L, and their cytotoxicity was higher than that of genipin; the product 1-O-(4'-ene-pentyl) genipin had no effect on the proliferation of cells at 200 μmol / L, and its cytotoxicity was lower than that of genipin, making it safer.
[0110] By testing the effect of genipin on the LPS-induced BV-2 inflammation model at concentrations of 3.125, 6.25, 12.5, 25, 50, and 100 μmol / L, it was found that the NO level was significantly affected at concentrations of 12.5, 25, 50, and 100 μmol / L compared with the model group (P < 0.01). The product 1-O-(3'-ene-butyl) genipin had an effect on the NO level of the LPS-induced BV-2 inflammation model at a drug concentration of 50 μmol / L (P < 0.05), and its relative inhibition rate was 74.27 ± 11.65%. 1-O-(4'-ene-pentyl) genipin had an effect on the NO level of the LPS-induced BV-2 inflammation model at a drug concentration of 50 μmol / L (P < 0.01), and the relative inhibition rate was 68.34 ± 10.26%, which was significantly different at this concentration. 1-O-(5'-ene-hexyl) genipin had an effect on the NO level in the LPS-induced BV-2 inflammation model at drug concentrations of 12.5, 25 μmol / L and 50 μmol / L (P<0.01), and the relative inhibition rates were 79.37±3.86%, 73.79±5.80% and 54.83±1.93%, respectively. 1-O-(3'-alkynyl-butyl) genipin had an effect on the NO level in the LPS-induced BV-2 inflammation model at drug concentrations of 12.5, 25 and 50 μmol / L (P<0.01), and the relative inhibition rates were 84.33±4.38%, 77.37±2.66% and 69.24±5.60%, respectively. 1-O-(5'-ene-hexyl) genipin has obvious dose dependence, while 1-O-(3'-alkyne-butyl) genipin is not obviously dose-dependent. By testing the saturated genipin derivative 1-O-methyl genipin at different concentrations on the LPS-induced BV-2 inflammation model, the results showed that the relative inhibition rates at concentrations of 12.5, 25, and 50 μmol / L were 80.14±6.62%, 77.94±7.64%, and 75.73±4.68%, respectively, and its inhibitory effect was less than that of 1-O-(5'-ene-hexyl) genipin.
[0111] The present invention synthesizes 4 genipin derivatives containing unsaturated groups after structural modification based on the parent nucleus of genipin: they all have the basic skeleton of cyclopentadiene, the hydroxyl group at the C-10 position and the esterified C-11 position, and the difference is the unsaturated group connected to the C-1 position, which leads to different anti-inflammatory activities on LPS-induced BV-2 cells. From the analysis of the preliminary cell experimental results, it can be concluded that 1-O-(5'-ene-hexyl) genipin has less cytotoxicity and the best anti-inflammatory activity; 1-O-(3'-ene-butyl) genipin has the worst anti-inflammatory activity, and can only achieve no cytotoxicity and anti-inflammatory activity when the drug concentration is 50μmol / L. The synthesized 4 genipin derivatives all have good anti-inflammatory activity when the drug concentration is 50μmol / L, and further in-depth research can be conducted on them in the future.
[0112] Based on the core structure of genipin, the present invention selects two suitable catalysts for S N 1 and S N 2 substitution reaction, and finally synthesized 4 genipin derivatives containing unsaturated groups. Preliminary experiments showed that it has the effect of reducing the NO level of inflammatory cells without affecting the survival rate of BV-2 cells. These findings can pave the way for later research on anti-brain cell inflammation.
[0113] Neuroinflammation is a common pathophysiological phenomenon in the central nervous system, which is involved in almost all neurological and psychiatric diseases and has an important impact on the course and recovery of the disease. Mediation or reduction of over-activated neuroinflammation is an important strategy to improve the recovery of central nervous system diseases. BV-2 cells are the main source of inflammatory factors, and neuroinflammation caused by their over-activation is the key to many nervous system diseases. The unsaturated group-containing genipin derivatives synthesized by the present invention have a certain anti-inflammatory effect on LPS-induced BV-2 cells, and the preliminary activity evaluation found that they have a certain anti-inflammatory effect on LPS-induced BV-2 cells, which lays a foundation for the future development of new genipin derivatives with less toxicity and better anti-inflammatory activity.
[0114] Although the above-mentioned embodiments have made a detailed description of the present invention, they are only some embodiments of the present invention, rather than all embodiments. People can also obtain other embodiments based on the embodiments of the present invention without creative work, and these embodiments all fall within the scope of protection of the present invention.
Claims
1. A genipin derivative, characterized in that The structural formula is shown in Formula I: In formula I, R is H2C=CH-CH2-CH2-, H2C=CH-CH2-CH2-CH2-, H2C=CH-CH2-CH2-CH2-, H2C=CH-CH2-CH2-CH2-CH2- or CH≡C-CH2-CH2-.
2. The method for preparing the genipin derivative according to claim 1, characterized in that: The following steps are involved: Genipin, alcohol, organic solvent and catalyst are mixed for substitution reaction to obtain a genipin derivative; the alcohol includes an enol or an alkynol, the enol includes 3-butene-1-ol, 4-pentene-1-ol or 5-hexene-1-ol, and the alkynol includes 3-butyn-1-ol.
3. The preparation method according to claim 2, characterized in that: When the alcohol is an enol, the catalyst is p-toluenesulfonic acid.
4. The preparation method according to claim 3, characterized in that: The molar ratio of genipin to p-toluenesulfonic acid is 1:1.1 to 1:
5.
5. The preparation method according to claim 2, characterized in that: When the alcohol is an alkynol, the catalyst is boron trifluoride etherate.
6. The preparation method according to claim 5, characterized in that: The molar ratio of genipin to boron trifluoride ether is 1:1.1 to 1:
5.
7. The preparation method according to any one of claims 2 to 6, characterized in that: The temperature of the substitution reaction is -20 to 0°C and the time is 4 to 5 hours.
8. The preparation method according to claim 2, characterized in that: The organic solvent includes dichloromethane or dichloroethane, and the usage ratio of genipin to the organic solvent is 1 mmol: (5-20) mL.
9. The preparation method according to claim 2, characterized in that: The substitution reaction also includes quenching reaction, extraction, drying and purification. The purification is silica gel column purification. The eluent of the silica gel column purification is a mixture of petroleum ether and ethyl acetate. The volume ratio of petroleum ether to ethyl acetate in the mixture is 3:1 to 8:
1.
10. Use of the genipin derivative according to claim 1 or the genipin derivative obtained by the preparation method according to any one of claims 2 to 9 in the preparation of a drug for treating central nervous system inflammation.
Citation Information
Patent Citations
Genipin methyl ether, preparation method and medicine application thereof
CN102875518A
Genipin derivative and application thereof
CN102993158A
Genipin derivatives and their preparation method and use
CN107382951A
1-O-alkyl genipin and preparation method and application thereof
CN113831316A
